missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ SIGLEC15 Biosimilar Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody
500.00€ - 1262.00€
Especificaciones
| Antígeno | SIGLEC15 Humanized Biosimilar |
|---|---|
| Concentración | 1 mg/mL |
| Contenido y almacenamiento | -20°C, Avoid Freeze/Thaw Cycles |
| Aplicaciones | ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance |
| Clasificación | Recombinant Monoclonal |
| Código de producto | Marca | Cantidad | Precio | Cantidad y disponibilidad | |||||
|---|---|---|---|---|---|---|---|---|---|
| Código de producto | Marca | Cantidad | Precio | Cantidad y disponibilidad | |||||
30284204
![]() |
Invitrogen™
MA559771 |
100 μg |
500.00€
100 microgramos |
Por favor, inicie sesión para comprar este producto. ¿No tiene usuario web? Regístrese hoy mismo. | |||||
|
30283227
|
Invitrogen™
MA559772 |
1 mg |
1262.00€
1 miligramo |
Por favor, inicie sesión para comprar este producto. ¿No tiene usuario web? Regístrese hoy mismo. | |||||
Descripción
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °. This antibody can also be cross referenced by the term AB-25E9.
SIGLEC15 (Sialic acid-binding immunoglobulin-like lectin 15) is a member of the Siglec family, which is primarily involved in immune cell signaling and modulation. It is located on chromosome 18q12.2 and is highly expressed in myeloid cells, including macrophages and dendritic cells. Structurally, Siglec-15 contains a V-set and a C2-set immunoglobulin-like domain, a transmembrane domain, and a cytoplasmic domain containing immunoreceptor tyrosine-based inhibition motifs (ITIMs). Functionally, Siglec-15 plays a crucial role in osteoclast differentiation and bone resorption, as well as in modulating immune responses. It enhances tumor immune escape by suppressing T cell activation and has been identified as a potential target for cancer immunotherapy. Overexpression of Siglec-15 is associated with various cancers, infectious diseases, and bone metabolic disorders.Especificaciones
| SIGLEC15 Humanized Biosimilar | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Recombinant Monoclonal | |
| Lyophilized | |
| IgG1 | |
| Human | |
| Primary | |
| Protein A |
| 1 mg/mL | |
| ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance | |
| Unconjugated | |
| Human | |
| RUO | |
| 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 | |
| Antibody |
¿Detecta una oportunidad de mejora?Comparta una corrección de contenido
Corrección del contenido de un producto
Proporcione sus comentarios sobre el contenido del producto rellenando el siguiente formulario.
Título del producto